The Quantellect read.As of Nov 19, 2026, 3 active firms cover Autolus Therapeutics Ltd: 3 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $10.00 to $10.00, so the covering firms are broadly aligned. The average target of $10.00 sits 839% above the current $1.06. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near 72% this year and 48% next, consensus EPS building from about $-0.18 next quarter toward $-0.57 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 active firms
Buy
Strong Buy00%
Buy3100%
Neutral00%
Sell00%
Strong Sell00%
Based on 3 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$10.00
+839.0% upside
Average target across 2 active firms as of Nov 19, 2026 vs $1.07 current
Highest Target$10.00
Average Target$10.00
Lowest Target$10.00
Detailed analyst forecasts for AUTL
Showing 1–2 of 2 named analysts shown · 3 active firms in the rating projection
As of Nov 19, 2026, 3 of 3 active firms rate AUTL a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
AUTL EPS & revenue forecast
EPS · NEXT QUARTER
$-0.18
Range $-0.21 – $-0.12 · 4 analysts · -48% YoY
Next period, 4 analysts expect Autolus Therapeutics Ltd to earn $-0.18 a share (range $-0.21 – $-0.12), versus $-0.34 a year earlier. Full-year consensus is $-0.80, growing to $-0.57 the year after.
REVENUE · NEXT QUARTER
$42.4M
Range $38.4M – $45.4M · 4 analysts · +45% YoY
Revenue is expected to reach $42.4M (range $38.4M – $45.4M), +45.0% year-over-year. Full-year consensus is $151.8M, rising to $196.6M next year.
Top analysts covering Autolus Therapeutics Ltd
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on AUTL.
#1
Gil Blum
Needham · Rank #409
Buy
$10.00+839.0% to target
Overall win rate
27%
+ Follow
#2
Emily Bodnar
HC Wainwright & Co. · Rank #521
Buy
$10.00+839.0% to target
Overall win rate
24%
+ Follow
#3
Salim Syed
Mizuho
Buy
$10.00+839.0% to target
Coverage
—
+ Follow
#4
RS
Rajan Sharma
Goldman Sachs
Buy
$5.80+444.6% to target
Coverage
—
+ Follow
#5
Asthika Goonewardene
Truist Securities
Buy
$8.00+651.2% to target
Coverage
—
+ Follow
AUTL stock forecast FAQ
What is AUTL's average 12-month price target?+
The 2 active firms with a live target average $10.00 for Autolus Therapeutics Ltd over the next 12 months, ranging from a $10.00 high to a $10.00 low, as of Nov 19, 2026.
Is AUTL stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 3 active firms as of Nov 19, 2026, 3 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover AUTL?+
3 active firms have a recognized rating on Autolus Therapeutics Ltd as of Nov 19, 2026, and 2 active firms carry a live 12-month price target.
Who is the most accurate analyst covering AUTL?+
Among analysts who currently cover AUTL, Gil Blum of Needham has the strongest overall Quantellect track record (Rank #409). Their current call is Buy with a $10.00 target.
What is Autolus Therapeutics Ltd's projected EPS for next quarter?+
The consensus estimate is $-0.18 per share (range $-0.21 – $-0.12) across 4 analysts. Full-year EPS is projected at $-0.80, rising to $-0.57 the following year.
How much revenue is Autolus Therapeutics Ltd expected to report next quarter?+
Consensus revenue is $42.4M (range $38.4M – $45.4M). Full-year revenue is projected at $151.8M, growing to $196.6M next year.
Have analysts been upgrading or downgrading AUTL lately?+
As of Nov 19, 2026, 3 of 3 active firms rate AUTL a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their AUTL calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.